In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE Healthcare Sets Out Its Software And AI Ambitions

Executive Summary

GE Healthcare is using its artificial intelligence platform Edison to power a new generation of medical imaging apps and devices. At the annual European Congress of Radiology (ECR), In Vivo met with Mathias Goyen, GE Healthcare’s chief medical officer, Europe, to discuss the future of AI in radiology and how technology will transform practice.

You may also be interested in...



GE Deals Biopharma Biz To Danaher For $21.4Bn; Planned Healthcare IPO Probably Won't Happen

The proposed IPO for GE's healthcare business could be off the table, CEO Lawrence Culp said as GE announced plans to sell its biopharma business to Danaher for $21.4bn. The deal will provide the conglomerate with a much needed cash injection to handle its rising debts.

GE And Roche Join Forces In First-Of-Its-Kind Tech Pact

The goliaths of imaging and in vitro diagnostics have sealed a pact to codevelop a new data analytics platform for faster clinical decision-making, more accurate diagnosis and more personalized treatments.

Exec Chat: Boston Scientific’s Angelo De Rosa Forsees Digital Transformation In The COVID-19 Era

Angelo De Rosa, VP of Boston Scientific's cardiac rhythm management business in Europe, the Middle East and Africa, talked to Medtech Insight about the opportunities to accelerate digital transformation in health care during the COVID-19 crisis.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel